NCT03794206终止不适用
CD 1009 Rev A Page 1 of 44 23OCT2018 Vesair Balloon Confirmatory Trial (VECTOR) Use of the Next Generation Vesair® Bladder Control System for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 20
- 试验地点
- 15
- 主要终点
- Provocative Pad Weight
研究概览
简要总结
Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI) with follow-up at 1, 3 and 12 months. All subjects will be prospectively treated after the subject has provided informed consent and determination that all study entry criteria have been met.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Previously treated with Vesair Balloon within the past 4 years
- •Normal voiding function
- •Has signed consent
- •Willing to undergo cystoscopy
- •Available for minimum of 12 months
排除标准
- •Last Menstrual Period within past 4 years
- •Systemic birth control medication (including implants) or systemic hormone replacement therapy (estrogen or progesterone) in the past 4 years.
- •History of urosepsis, bladder infection, urinary tract infection or asymptomatic bacteriuria within the past 3 months.
- •Urinary incontinence of neurogenic etiology.
- •Prior pelvic surgery that may affect incontinence symptoms (including placement and/or removal of a suburethral sling) within the past 4 years.
- •Noninvasive treatment for incontinence, such as nerve stimulation, Botox injections, biofeedback, formal pelvic floor muscle training, and/or vaginal laser therapy, within the past 3 months.
- •Taken medications other than anticholinergics that may affect SUI symptoms (such as enobosarm, duloxetine or imipramine) in the past 3 months.
- •Taking other pharmacologic agents that may have a significant effect on bladder function unless on the therapy for at least 3 months and intending to continue the same dosage of the medication throughout the trial.
- •History of recurrent (>1) kidney stones, or one kidney stone within the past 5 years.
- •History of an artificial urinary sphincter.
- •Presence of gross hematuria and/or blood clots in the urine.
- •History of interstitial or follicular cystitis or other painful bladder syndrome.
- •Cystocele verified as Stage 3 or higher by PoP-Q Classification.
- •Local genital skin infection.
- •Urethral or bladder inflammation and/or edema, or other hypersensitivity to cystoscopy or other urethral manipulations.
- •Evidence of involuntary detrusor contractions and/or discomfort during bladder filling up to 300cc.
- •Undergoing or anticipating a course of pelvic radiation therapy or with severe pelvic fibrosis from previous radiation therapy.
- •Non-ambulatory, bedridden or physically unable to complete test exercises.
- •History of recent alcoholism or illicit drug abuse within the last year.
- •Immunologically suppressed or immunocompromised.
- •History of any neurological disease that could impact bladder function including Parkinson's disease, multiple sclerosis or post-stroke sequelae.
- •Uncontrolled diabetes (persistent A1C levels >9 percent).
- •History of any malignancy (except non-melanoma skin cancer), unless the cancer was not in the urinary tract, the cancer was stage II or less, the cancer was treated with curative intent, AND there have been no clinical signs or symptoms of the malignancy for at least 2 years.
- •Morbid obesity, defined as BMI ≥40.
- •History of any autoimmune or connective tissue disease or disorder that could impact bladder function
结局指标
主要结局
Provocative Pad Weight
时间窗: 3 months
in-office Pad weight test
次要结局
未报告次要终点
研究者
研究点 (15)
Loading locations...
相似试验
终止
不适用
Vesair Clinical TrialStress Urinary IncontinenceNCT04026347Solace Therapeutics, Inc.158
进行中（未招募）
不适用
Prospective multicentric evaluation of a bladder preservation strategy using a combination of neoadjuvant chemotherapy with intensified MVAC (Méthotrexate + vinblastine + adriamicine + Cisplatine) and optimal bladder transurethral resection in patients with a localized muscle infiltrative urothelial carcinoma (protocol ReChiVe) - ReChiVebladder infiltrative urothelium carcinomaMedDRA version: 12.0Level: LLTClassification code 10005021Term: Bladder carcinoma stage IIEUCTR2009-014264-19-FRClinique Mutualiste Chirurgicale
招募中
不适用
The Purpose of This Study is to Assess Clinical Efficacy and Safety of Berovenal® Intended to Promote Treatment and to Expedite Chronic Diabetic Foot Ulcer HealingDiabetic Foot UlcerNCT06584617VULM s.r.o.66
撤回
不适用
Study to Determine Pediatric Bladder Volume Prior to CatheterizationUrinary Tract InfectionNCT00847392Hamilton Health Sciences Corporation
尚未招募
不适用
BRAVO study: Bladderscan validation study for asymptomatic postpartum urinary retentioAsymptomatic postpartum urinary retentioninadequate voiding after delivery10010273NL-OMON37324Catharina-ziekenhuis1,000